We are pleased to announce that U.S. Senator Angus King (I-ME) has received the Prescription Justice 5-star rating based on his full support of the organization’s Policy Platform to lower drug prices here and expand access to safe and affordable medication from other countries. Senator King’s 5-star rating reflects his unwavering support of commonsense policy solutions to end the prescription drug affordability crisis. Members of Congress get one star for their positions on the following:
1. Recognizes that the United States is suffering from a crisis of high drug prices?
2. Ending the ban that prevents Medicare from negotiating lower drug prices with pharmaceutical companies;
3. Making reverse payment arrangements between brand and generic companies, also known as “pay-for-delay” illegal;
4. Legalizing the importation of lower-cost medication from Canada and other countries with similarly strict pharmaceutical regulations; and 5. Using reasonable, commonsense, and compassionate enforcement discretion to permit individuals to import small quantities of affordable medication to fill prescriptions. (more…)
Prescription Justice has endorsedRyan Watts for the U.S. House of Representatives in the 6th District of North Carolina based on his pro-patient/pro-consumer stance to address the prescription drug price crisis in America.
Ryan Watts fully supports the Prescription Justice Policy Platform to permit Medicare to negotiate drug prices; ending “pay-for-delay” deals by pharmaceutical companies that prevent lower cost generics from coming to market; legalizing importation of lower-cost and safe medication; and expressly permitting personal importation now from licensed pharmacies as a lifeline of affordable medication. (more…)
Last Friday, President Trump unveiled his blueprint to lower drug prices named American Patients First. Sadly, the Administration’s plan excludes Trump’s campaign promises to use the massive buying power of the government's Medicare program to negotiate lower prices for older Americans and provide greater access to imported, lower-cost medications. (more…)
As President Donald Trump gives his big speech on drug prices today, we're going to highlight a young candidate for U.S. Congress who is clearly on the side of the people on the issue of drug prices. Ryan Watts, Democratic candidate for Congress in the 6th District of North Carolina, became the first candidate to complete the Prescription Justice Drug Prices Policy Platform Questionnaire, a national bipartisan effort to provide members of Congress and candidates for statewide and federal offices an opportunity to state their position on the Prescription Justice policy platform. (more…)
A group of over 50 healthcare providers, including physicians, nurses and physician assistants, have come together to demand the federal government stop any action that would restrict access to lifesaving medications through personal prescription importation.
In a letter sent to President Donald Trump, members of Congress and the Food and Drug Administration (FDA), the healthcare providers expressed their alarm over FDA’s action in Florida against offices that primarily serve older Americans who prefer in-person assistance with purchasing medications from Canada and other countries, rather than using an internet site. Last year, FDA agents armed with search warrants notified the office owners that importing drugs is illegal and those who help “administer” such drugs could face fines or jail time. Yet, according to its owners, these offices do not dispense or administer medication to patients. (more…)
Prescription Justice heartily endorses Utah bill HB 163, The Prescription Drug Affordability Act, and applauds Utah Representative Norman Thurston (R-63), its lead sponsor. The bill envisions the federal government permitting Utah to import wholesale quantities of FDA-approved drugs from Canada, which would then be dispensed to patients at retail pharmacies and hospitals in Utah. Canadian wholesale pharmacy prices are much lower on many expensive brand name drugs. Utahans would stand to save hundreds of millions of dollars on their collective pharmacy bill.
The bill’s passage would authorize a study, one lead by the Utah Department of Health on the creation of a wholesale drug importation program, one that would operate in accordance with U.S. law. Specifically, Section 804 of the Food, Drug and Cosmetic Act, called Importation of Prescription Drugs, makes wholesale and personal importation of prescription drugs from Canada lawful – but only if the Secretary of Health and Human Services certifies that the practice poses no additional risk to the public’s health and safety and will result in a significant reduction in the cost of covered products to the American consumer. HB 163 endeavors that Utah’s program will receive such certification. (more…)
Prescription Justice recently joined with nine other health, social justice and consumer advocacy organizations to launch a petition to demand Congress act to bring relief to the millions of Americans who can't afford the prescription drugs they need.
The online petition largely echoes the Prescription Justice policy platform which prioritizes ending the ban on Medicare negotiating drug prices, making pay-for-delay deals illegal, and permitting wider access to lower-cost, imported medication through legislative, regulatory, and policy reforms. (more…)
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump's nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt's Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar's confirmation.
President Trump reinvigorated the drug price policy debate by recently stating that prescription drug prices "are out of control" and, for a second time, that drug companies are "getting away with murder". He's expected to soon announce a bi-partisan drug price task force to examine prescription drug costs. The president's renewed focus on lowering drug costs is a relief from the misaligned priority of healthcare reform, which seems to have overshadowed Americans most pressing healthcare concern: soaring drug costs.
In his most recent remarks, President Trump focused on the fact that prescription drugs are much cheaper in other countries. In fact, it's common for brand-name prescription drug prices to be as much as 90 percent lower in pharmacies outside the U.S., which is why millions of Americans, despite federal restrictions, have had to import medication from Canada and elsewhere. Unfortunately, the law and misleading public information campaigns sponsored by drug companies scare Americans away from more affordable medication. (more…)
During a press conference today, Representatives Elijah Cummings (D-MD), Peter Welch (D-VT) and Lloyd Doggett (D-TX), joined Senator Bernie Sanders (I-VT) to introduce new legislation aimed at lowering the high cost of prescription drugs for the 41 million Medicare enrollees. Medicare is the largest purchaser of prescription medications, however it is expressly prohibited from negotiating with pharmaceutical companies over the price of medications.
The Medicare Drug Price Negotiations Act would amend Title XVIII of the Social Security Act by removing the non-interference clause, which expressly bans Medicare from negotiating drug prices. The bill instructs the Secretary of the Health and Human Services to negotiate for Part D drugs, either by creating a national formulary or instructing Prescription Drug Plans (PDPs) to makes changes to their formularies. (more…)